{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:34:39Z","timestamp":1789122879405,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008321","name":"Pennsylvania State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Drug Policy"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.drugpo.2019.06.019","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T22:45:36Z","timestamp":1563576336000},"page":"118-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["\u201cThey're making it so hard for people to get help:\u201d Motivations for non-prescribed buprenorphine use in a time of treatment expansion"],"prefix":"10.1016","volume":"71","author":[{"given":"Katherine","family":"McLean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip R.","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugpo.2019.06.019_bib0005","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/08897077.2015.1065541","article-title":"Interim buprenorphine treatment in opiate dependence: A pilot effectiveness study","volume":"37","author":"Abrahamsson","year":"2016","journal-title":"Substance Abuse"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0010","series-title":"Joint position statement on medication-assisted treatment for opioid use disorders in Allegheny county","author":"Allegheny County Health Department","year":"2017"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0015","series-title":"Year end annual report 2016","author":"Allegheny Health Choices","year":"2017"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0020","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jsat.2016.08.002","article-title":"Non-prescribed buprenorphine in New York City: Motivations for use, practices of diversion, and experiences of stigma","volume":"70","author":"Allen","year":"2016","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0025","series-title":"Summary of the comprehensive addiction and recovery act","author":"American Society for Addiction Medicine","year":"2018"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0030","series-title":"Gov. Wolf declares a disaster emergency over opioid crisis","author":"Associated Press","year":"2018"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0035","series-title":"2018 annual surveillance report of drug-related risks and outcomes, United States: Surveillance special report","author":"Centers for Disease Control and Prevention","year":"2018"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0040","series-title":"Use of addiction treatment medications in the treatment of pregnant patients with opioid use disorders","author":"Commonwealth of Pennsylvania","year":"2016"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0045","series-title":"Emergency department (ED) prescribing guidelines","author":"Commonwealth of Pennsylvania","year":"2018"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0050","first-page":"403","article-title":"\u201cSub is a weird drug:\u201d A web-based study of lay attitudes about use of buprenorphine to self-treat opioid withdrawal symptoms","volume":"24","author":"Daniulaityte","year":"2015","journal-title":"The American Journal on Addictions \/ American Academy of Psychiatrists in Alcoholism and Addictions"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0055","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.drugalcdep.2011.09.029","article-title":"Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids","volume":"122","author":"Daniulaityte","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0060","series-title":"The opioid threat in Pennsylvania: Joint intelligence report (No. DEA-PHL-DIR-036-1)","author":"DEA Philadelphia Division, & Pitt Pharmacy","year":"2018"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0065","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1001\/jama.2015.3474","article-title":"Emergency department-initiated buprenorphine\/naloxone treatment for opioid dependence: A randomized clinical trial","volume":"313","author":"D\u2019Onofrio","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0070","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/002204269802800206","article-title":"Accessing drug-abuse treatment: Perceptions of out-of-treatment injectors","volume":"28","author":"Farabee","year":"1998","journal-title":"Journal of Drug Issues"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0075","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jsat.2014.07.015","article-title":"Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants","volume":"48","author":"Fox","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0080","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/1475-6773.00151","article-title":"Accessibility of addiction treatment: Results from a national survey of outpatient substance abuse treatment organizations","volume":"38","author":"Friedmann","year":"2003","journal-title":"Health Services Research"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0085","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa022164","article-title":"Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone","volume":"349","author":"Fudala","year":"2003","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0090","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/10550887.2012.759860","article-title":"Suboxone misuse along the opiate maintenance treatment pathway","volume":"32","author":"Furst","year":"2013","journal-title":"Journal of Addictive Diseases"},{"issue":"3","key":"10.1016\/j.drugpo.2019.06.019_bib0095","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/10550887.2014.950030","article-title":"Diffusion and diversion of suboxone: An exploration of illicit street opioid selling","volume":"33","author":"Furst","year":"2014","journal-title":"Journal of Addictive Diseases"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0100","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1016\/j.addbeh.2013.08.008","article-title":"Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland","volume":"38","author":"Genberg","year":"2013","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0105","series-title":"Legislators are pushing Pennsylvania backward on opioids. | Opinion","author":"Gutman","year":"2018"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0110","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.drugalcdep.2017.08.019","article-title":"The relationship between treatment accessibility and preference amongst out-of-treatment individuals who engage in non-medical prescription opioid use","volume":"180","author":"Huhn","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0115","series-title":"The availability of medication-assisted treatment for opioid addiction in Pennsylvania","author":"Holt","year":"2019"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0120","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.drugalcdep.2017.06.033","article-title":"Abuse liability of intravenous buprenorphine vs. buprenorphine\/naloxone: Importance of absolute naloxone amount","volume":"179","author":"Jones","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0125","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.drugalcdep.2015.09.032","article-title":"States\u2019 implementation of the Affordable Care Act and the supply of physicians waivered to prescribe buprenorphine for opioid dependence","volume":"157","author":"Knudsen","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0130","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.drugalcdep.2012.05.025","article-title":"Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine","volume":"126","author":"Lofwall","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0135","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0140","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3109\/10826089909037242","article-title":"Drug treatment experiences: Rural and urban comparisons","volume":"34","author":"Metsch","year":"1999","journal-title":"Substance Use & Misuse"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0145","series-title":"Patient protection and affordable care act, 42 U.S.C. \u00a7 18001 \u00a7","author":"Patient Protection and Affordable Care Act","year":"2010"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0150","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.drugpo.2008.07.004","article-title":"Why don\u2019t out-of-treatment individuals enter methadone treatment programmes?","volume":"21","author":"Peterson","year":"2010","journal-title":"The International Journal of Drug Policy"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0155","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1177\/002204260603600404","article-title":"Waiting time as a barrier to treatment entry: Perceptions of substance users","volume":"36","author":"Redko","year":"2006","journal-title":"Journal of Drug Issues"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0160","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1370\/afm.1735","article-title":"Geographic and specialty distribution of US physicians trained to treat opioid use disorder","volume":"13","author":"Rosenblatt","year":"2015","journal-title":"Annals of Family Medicine"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0165","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.drugpo.2015.12.024","article-title":"Non-prescribed use of opioid substitution medication: Patterns and trends in sub-populations of opioid users in Germany","volume":"29","author":"Schulte","year":"2016","journal-title":"The International Journal of Drug Policy"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0170","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jsat.2010.03.014","article-title":"Self-treatment: Illicit buprenorphine use by opioid-dependent treatment seekers","volume":"39","author":"Schuman-Olivier","year":"2010","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0175","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2105\/AJPH.2012.301049","article-title":"Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009","volume":"103","author":"Schwartz","year":"2013","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0180","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2014.2421","article-title":"The Untapped potential of office-based buprenorphine treatment","volume":"72","author":"Sigmon","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0185","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addbeh.2015.07.030","article-title":"Bridging waitlist delays with interim buprenorphine treatment: Initial feasibility","volume":"51","author":"Sigmon","year":"2015","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0190","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1001\/jama.2016.10542","article-title":"Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment","volume":"316","author":"Stein","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0195","series-title":"BHSIS series S-93, HHS publication No. (SMA) 17-5039","article-title":"National survey of substance abuse treatment services (N-SSATS): 2016. Data on substance abuse treatment facilities","author":"Substance Abuse and Mental Health Services Administration","year":"2017"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0200","series-title":"BHSIS series S-95, HHS publication No. (SMA) 17-4360","article-title":"Treatment episode data set (TEDS): 2003-2013. State admissions to substance abuse treatment services","author":"Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality","year":"2017"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0205","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.drugalcdep.2017.10.002","article-title":"Prescribing patterns of buprenorphine waivered physicians","volume":"181","author":"Thomas","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0210","series-title":"Should patients in drug treatment need to go through counseling?","author":"Thomasson","year":"2018"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0215","series-title":"National survey on drug use and health","author":"United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics and Quality","year":"2016"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0220","series-title":"Facing addiction in America: The surgeon general\u2019s spotlight on opioids","author":"U.S. Department of Health and Human Services (HHS), Office of the Surgeon General","year":"2018"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0225","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.2943","article-title":"Association of buprenorphine-waivered physician supply with buprenorphine treatment use and prescription opioid use in Medicaid enrollees","volume":"1","author":"Wen","year":"2018","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/02791072.1994.10472597","article-title":"Drug treatment on demand\u2014Not","volume":"26","author":"Wenger","year":"1994","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/j.drugpo.2019.06.019_bib0235","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3109\/00952999709016892","article-title":"Injecting drug users who want treatment","volume":"23","author":"Zule","year":"1997","journal-title":"The American Journal of Drug and Alcohol Abuse"}],"container-title":["International Journal of Drug Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395919301744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395919301744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T15:44:28Z","timestamp":1760629468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955395919301744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":47,"alternative-id":["S0955395919301744"],"URL":"https:\/\/doi.org\/10.1016\/j.drugpo.2019.06.019","relation":{},"ISSN":["0955-3959"],"issn-type":[{"value":"0955-3959","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cThey're making it so hard for people to get help:\u201d Motivations for non-prescribed buprenorphine use in a time of treatment expansion","name":"articletitle","label":"Article Title"},{"value":"International Journal of Drug Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugpo.2019.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}